The role of methotrexate in osteosarcoma

J Natl Cancer Inst. 1988 Jul 6;80(9):626-55. doi: 10.1093/jnci/80.9.626.


High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic issues concerning MTX therapy in osteosarcoma are discussed.

Publication types

  • Clinical Trial
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Humans
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use*
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / surgery


  • Methotrexate